Tozorakimab for pulmonary disease, chronic obstructive

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 6 registered trials.

Why this status

  1. 15 Dec 2021: Trial registered, NCT05158387
  2. 22 Dec 2021: Trial registered, NCT05166889
  3. 3 Jan 2022: Trial started, NCT05166889
  4. 7 Feb 2022: Trial started, NCT05158387
  5. 24 Feb 2023: Trial registered, NCT05742802
  6. 6 Mar 2023: Trial started, NCT05742802
  7. 15 Sep 2023: Trial registered, NCT06040086
  8. 22 Sep 2023: Trial started, NCT06040086
  9. 4 May 2026: Trial registered, NCT07566195
  10. 5 May 2026: Trial started, NCT07566195

The trials

NCT05158387: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.

State
Completed
Phase
Phase 3
People
1,172 taking part
Started
7 Feb 2022
Primary completion
19 Jan 2026
Arms
Tozorakimab Dose 1, Tozorakimab Dose 2
Results
None posted
Papers
doi:10.1056/nejmoa2606998, doi:10.1136/bmjresp-2026-004145
  1. 15 Dec 2021: Trial registered
  2. 7 Feb 2022: Trial started
  3. 22 Mar 2026: Trial completed

NCT05166889: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

State
Completed
Phase
Phase 3
People
1,132 taking part
Started
3 Jan 2022
Primary completion
19 Jan 2026
Arms
Tozorakimab Dose 1, Tozorakimab Dose 2
Results
None posted
Papers
doi:10.1056/nejmoa2606998, doi:10.1136/bmjresp-2026-004145
  1. 22 Dec 2021: Trial registered
  2. 3 Jan 2022: Trial started
  3. 11 Mar 2026: Trial completed

NCT05742802: Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).

State
Completed
Phase
Phase 3
People
1,713 taking part
Started
6 Mar 2023
Primary completion
26 Feb 2026
Arms
Tozorakimab Dose 1, Tozorakimab Dose 2
Results
None posted
Papers
doi:10.1136/bmjresp-2026-004145
  1. 24 Feb 2023: Trial registered
  2. 6 Mar 2023: Trial started
  3. 27 May 2026: Trial completed

NCT06040086: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations

State
Completed
Phase
Phase 3
People
1,454 taking part
Started
22 Sep 2023
Primary completion
6 Mar 2026
Arms
Tozorakimab
Results
None posted
Papers
doi:10.1136/bmjresp-2026-004145
  1. 15 Sep 2023: Trial registered
  2. 22 Sep 2023: Trial started
  3. 22 May 2026: Trial completed

NCT06897748: A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils

State
Completed
Phase
Phase 2
People
98 taking part
Started
12 Apr 2025
Primary completion
21 Apr 2026
Arms
Tozorakimab
Results
None posted
  1. 27 Mar 2025: Trial registered
  2. 12 Apr 2025: Trial started
  3. 21 Apr 2026: Trial completed

NCT07566195: Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations

State
Under way
Phase
Phase 3
People
59 planned
Started
5 May 2026
Primary completion
29 Dec 2028
Arms
Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2
Results
None posted
  1. 4 May 2026: Trial registered
  2. 5 May 2026: Trial started

How the status changed

  1. 16 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Tozorakimab 1, Tozorakimab 2, Tozorakimab Dose Regimen 1, Tozorakimab Dose Regimen 2.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.